Garderet, L., Iacobelli, S., Moreau, P., Dib, M., Lafon, I., Niederwieser, D., et al. (2012). Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. JOURNAL OF CLINICAL ONCOLOGY, 30(20), 2475-2482 [10.1200/JCO.2011.37.4918].
Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
IACOBELLI, SIMONA;
2012-01-01
File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Garderet_MMVAR_JCO 2012.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
194.39 kB
Formato
Adobe PDF
|
194.39 kB | Adobe PDF | Visualizza/Apri |
Garderet_MMVAR_JCO editorial May 2012.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
141.79 kB
Formato
Adobe PDF
|
141.79 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.